CTI BioPharma Corp (NASDAQ:CTIC) shares saw unusually-strong trading volume on Monday following insider buying activity. Approximately 6,125,700 shares changed hands during trading, an increase of 1,289% from the previous session’s volume of 441,031 shares.The stock last traded at $3.21 and had previously closed at $3.21.

Specifically, major shareholder Bvf Partners L. P/Il acquired 5,634,108 shares of the company’s stock in a transaction on Friday, February 9th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $16,902,324.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 6,333,333 shares of the company’s stock in a transaction on Friday, February 9th. The stock was acquired at an average price of $3.00 per share, for a total transaction of $18,999,999.00. The disclosure for this purchase can be found here. Insiders own 2.16% of the company’s stock.

Separately, Zacks Investment Research upgraded shares of CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, December 27th.

The company has a debt-to-equity ratio of 0.26, a current ratio of 2.19 and a quick ratio of 2.17.

Several institutional investors have recently modified their holdings of the company. OxFORD Asset Management LLP acquired a new position in shares of CTI BioPharma during the third quarter worth about $164,000. JPMorgan Chase & Co. acquired a new position in shares of CTI BioPharma during the third quarter worth about $272,000. Renaissance Technologies LLC increased its stake in shares of CTI BioPharma by 48.3% during the fourth quarter. Renaissance Technologies LLC now owns 609,849 shares of the biopharmaceutical company’s stock worth $1,634,000 after acquiring an additional 198,700 shares during the period. Kennedy Capital Management Inc. acquired a new position in shares of CTI BioPharma during the fourth quarter worth about $660,000. Finally, Stonepine Capital Management LLC increased its stake in shares of CTI BioPharma by 84.8% during the fourth quarter. Stonepine Capital Management LLC now owns 1,834,838 shares of the biopharmaceutical company’s stock worth $4,917,000 after acquiring an additional 841,838 shares during the period. Institutional investors and hedge funds own 42.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/14/cti-biopharma-ctic-sees-unusually-high-trading-volume-following-insider-buying-activity.html.

CTI BioPharma Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.